- Home
- STBA vs ETNB Comparison
STBA vs ETNB Comparison
Compare STBA & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STBA
- ETNB
- Stock Information
- Founded
- STBA 1902
- ETNB 2018
- Country
- STBA United States
- ETNB United States
- Employees
- STBA N/A
- ETNB N/A
- Industry
- STBA Major Banks
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- STBA Finance
- ETNB Health Care
- Exchange
- STBA Nasdaq
- ETNB Nasdaq
- Market Cap
- STBA 1.5B
- ETNB 1.5B
- IPO Year
- STBA N/A
- ETNB 2019
- Fundamental
- Price
- STBA $37.30
- ETNB $14.83
- Analyst Decision
- STBA Hold
- ETNB Buy
- Analyst Count
- STBA 3
- ETNB 10
- Target Price
- STBA $42.00
- ETNB $22.31
- AVG Volume (30 Days)
- STBA 133.9K
- ETNB 9.5M
- Earning Date
- STBA 10-23-2025
- ETNB 11-06-2025
- Dividend Yield
- STBA 3.61%
- ETNB N/A
- EPS Growth
- STBA N/A
- ETNB N/A
- EPS
- STBA 3.40
- ETNB N/A
- Revenue
- STBA $388,489,000.00
- ETNB N/A
- Revenue This Year
- STBA $7.12
- ETNB N/A
- Revenue Next Year
- STBA $5.09
- ETNB N/A
- P/E Ratio
- STBA $11.09
- ETNB N/A
- Revenue Growth
- STBA 1.05
- ETNB N/A
- 52 Week Low
- STBA $30.84
- ETNB $4.16
- 52 Week High
- STBA $45.46
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- STBA 41.55
- ETNB 79.17
- Support Level
- STBA $36.84
- ETNB $14.67
- Resistance Level
- STBA $38.07
- ETNB $14.93
- Average True Range (ATR)
- STBA 0.78
- ETNB 0.09
- MACD
- STBA -0.17
- ETNB 0.06
- Stochastic Oscillator
- STBA 12.95
- ETNB 41.03
About STBA S&T Bancorp Inc.
S&T Bancorp Inc is a bank holding company. The company operates in five markets including Western Pennsylvania, Eastern Pennsylvania, Northeast Ohio, Central Ohio and Upstate New York. The company provides financial services with retail and commercial banking products, cash management services, trust and brokerage services. It operates only in one segment which is Community Banking. The company earns revenue from interest on loans and securities and fees charged for financial services provided to its customers.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).